- Home
- NXTC vs HIND Comparison
NXTC vs HIND Comparison
Compare NXTC & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- HIND
- Stock Information
- Founded
- NXTC 2015
- HIND N/A
- Country
- NXTC United States
- HIND United States
- Employees
- NXTC N/A
- HIND N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- HIND
- Sector
- NXTC Health Care
- HIND
- Exchange
- NXTC Nasdaq
- HIND Nasdaq
- Market Cap
- NXTC 12.8M
- HIND 10.3M
- IPO Year
- NXTC 2019
- HIND 2016
- Fundamental
- Price
- NXTC $4.85
- HIND $7.95
- Analyst Decision
- NXTC Strong Buy
- HIND
- Analyst Count
- NXTC 2
- HIND 0
- Target Price
- NXTC $25.50
- HIND N/A
- AVG Volume (30 Days)
- NXTC 18.5K
- HIND N/A
- Earning Date
- NXTC 11-06-2025
- HIND N/A
- Dividend Yield
- NXTC N/A
- HIND N/A
- EPS Growth
- NXTC N/A
- HIND N/A
- EPS
- NXTC N/A
- HIND N/A
- Revenue
- NXTC N/A
- HIND N/A
- Revenue This Year
- NXTC N/A
- HIND N/A
- Revenue Next Year
- NXTC N/A
- HIND N/A
- P/E Ratio
- NXTC N/A
- HIND N/A
- Revenue Growth
- NXTC N/A
- HIND N/A
- 52 Week Low
- NXTC $2.69
- HIND N/A
- 52 Week High
- NXTC $19.20
- HIND N/A
- Technical
- Relative Strength Index (RSI)
- NXTC 41.16
- HIND N/A
- Support Level
- NXTC $4.83
- HIND N/A
- Resistance Level
- NXTC $5.15
- HIND N/A
- Average True Range (ATR)
- NXTC 0.23
- HIND 0.00
- MACD
- NXTC -0.02
- HIND 0.00
- Stochastic Oscillator
- NXTC 7.14
- HIND 0.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.